20170406 Telix Logo.png
First Patient Dosed in Phase II Study of TLX250-CDx in Triple-Negative Breast Cancer
October 04, 2021 17:34 ET | Telix Pharmaceuticals Limited
MELBOURNE, Australia and LIÈGE, Belgium, Oct. 05, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) today announces that a first patient has been dosed...
Zenith Epigenetics Announces Dosing of First Patient in Triple Negative Breast Cancer Trial with Pfizer
June 27, 2019 08:30 ET | Zenith Capital Corp.
CALGARY, Alberta, June 27, 2019 (GLOBE NEWSWIRE) -- Zenith Epigenetics Ltd. (“Zenith” or the “Company”), a wholly-owned subsidiary of Zenith Capital Corp., announced today that it has dosed the...
Intensity Therapeutics, Inc.
Intensity Therapeutics Receives Fast Track Designation from U.S. FDA for Development of INT230-6 as Treatment for Relapsed or Metastatic Triple Negative Breast Cancer
April 17, 2019 07:35 ET | Intensity Therapeutics Inc
WESTPORT, Conn., April 17, 2019 (GLOBE NEWSWIRE) -- Intensity Therapeutics, Inc., a clinical-stage biotechnology company pioneering a novel, immune-based approach to treat solid tumor cancers...
Zenith Epigenetics Announces U.S. FDA Clearance of Investigational New Drug Application for ZEN-3694 in TNBC Program
March 18, 2019 09:00 ET | Zenith Capital Corp.
Pfizer / Zenith TNBC program collaboration on target to dose first patient in April 2019 Phase 2 mCRPC program and clinical data to be presented at AACR CALGARY, Alberta, March 18, 2019 (GLOBE...
Insight Genetics.png
Insight Genetics Launches First-of-its-kind Test for Triple Negative Breast Cancer
December 03, 2018 09:36 ET | Insight Genetics
NASHVILLE, Tenn., Dec. 03, 2018 (GLOBE NEWSWIRE) -- Insight Genetics, Inc. today announced the launch of its proprietary Insight TNBCtype™, a new test for categorizing triple negative breast cancer...
Zenith Epigenetics Announces Clinical Trial Collaboration with Pfizer
November 20, 2018 08:30 ET | Zenith Capital Corp.
Collaboration to evaluate ZEN-3694 in combination with Talazoparib in TNBC patients; Phase 1b/2 trial expected to initiate 1Q 2019 CALGARY, Alberta, Nov. 20, 2018 (GLOBE NEWSWIRE) -- Zenith...